FR901228, a novel antitumor bicyclic depsipeptide produced by chromobacterium violaceum no. 968. III. Antitumor activities on experimental tumors in mice

The Journal of Antibiotics

Volumn 47, Issue 3, 1994, Pages 315-323

  Ueda, Hirotsugu ^a   Manda, Toshitaka ^b   Matsumoto, Sanae ^b   Mukumoto, Sueo ^b   Nishigaki, Fusako ^b   Kawamura, Ikuo ^b   Shimomura, Kyoichi ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DEPSIPEPTIDE; FLUOROURACIL; FR 901228; MITOMYCIN C; NEW DRUG; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES TUMOR; CANCER CHEMOTHERAPY; CHROMOBACTERIUM; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG RESISTANCE; EXPERIMENTAL NEOPLASM; FEMALE; FIBROSARCOMA; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA L 1210; LEUKEMIA P 388; LUNG CARCINOMA; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETICULOSARCOMA; STOMACH ADENOCARCINOMA; TRANSPLANTABLE SOLID TUMORS; TUMOR RESISTANCE;

ANIMAL; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBIOTICS, PEPTIDE; CHROMOBACTERIUM; COLONIC NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLUOROURACIL; LEUKEMIA, EXPERIMENTAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, NUDE; MITOMYCIN; NEOPLASM TRANSPLANTATION; SARCOMA, EXPERIMENTAL;

EID: 0028267278     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.7164/antibiotics.47.315     Document Type: Article

References (14)

1. Denny, W. A.: New directions in the design and evaluation of anti-cancer drugs. Drug Design and Delivery 3: 99~124, 1988.
2. Bos, J. L.: The ras gene family and human carcinogenesis. Mutat. Res. 195: 255~271, 1988.
3. Ueda, H.; H. Nakajima, Y. Hori, T. Fujita, M. Nishimura, T. Goto & M. Okuhara: FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J. Antibiotics 47: 301~310, 1994.
4. Shigematsu, N.; H. Ueda, S. Takase, H. Tanaka, K. Yamamoto & T. Tada: FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. II. Structure determination. J. Antibiotics 47: 311~314, 1994.
5. Ueda, H.; H. Nakajima, Y. Hori, T. Goto & M. Okuhara: Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968, on Ha-ras transformed NIH3T3 cells. Biosci. Biotech. Biochem., to submitted.
6. Inaba, M.; R. Fujikura & Y. Sakurai: Comparative study on in vivo development of resistance to various classes of antitumor agents in P388 leukemia. Gann 70: 607~613, 1979.
7. Mitsuhashi, J. & M. Inaba: Mechanism for resistance to 5-fluorouracil in P388 leukemia cells. J. Pharmacobio Dyn. 14: 577~581, 1991.
8. Johnson, R. K.; M. P. Chitnis, W. M. Embrey & E. B. Gregory: In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia. Cancer Treat. Rep. 62: 1535~1547, 1978.
9. Wilkoff, L. J. & E. A. Dulmadge: Resistance and cross-resistance of cultured leukemia P388 cells to vincristine, adriamycin analogs and actinomycin D. J. Natl. Cancer Inst. 61: 1521~1524, 1978.
10. Raymond, M.; E. Rose, D. E. Housman & P. Gros: Physical mapping, amplification, and overexpression of the mouse mdr gene family in multidrug-resistant cells. Mol. Cell. Biol. 10: 1642~1651, 1990.
11. Goldin, A.; J. M. Venditti, J. S. Macdonald, F. M. Muggia, J. E. Henney & V. T. Devita: Current results of the screening programme at the division of cancer treatment. National Cancer Institute. Eur. J. Cancer 17: 129~142, 1981.
12. Staquet, M. J.; D. P. Byar, S. B. Green & M. Rozencweig: Clinical predictivity of transplantable tumor systems in selection of new drugs for solid tumors: Reply to a commentary. Cancer Treat. Rep. 6: 1339~1340, 1985.
13. Manda, T.; K. Shimomura, S. Mukumoto, K. Kobayashi, T. Mizota, O. Hirai, S. Matsumoto, T. Oku, F. Nishigaki, J. Mori & H. Kikuchi: Recombinant human tumor necrosis factor-α: evidence of an indirect mode of antitumor activity. Cancer Res. 47: 3707~3711, 1987.
14. Shimomura, K.; T. Manad, S. Mukumoto, K. Kobayashi, K. Nakano & J. Mori: Recombinant human tumor necrosis factor-α: thrombus formation is a cause of antitumor activity. Int. J. Cancer 41: 243~247, 1988.